On Monday, Piper Sandler adjusted its price outlook on CVS Health (NYSE:NYSE:CVS), reducing the price target to $64 from the previous $72. Despite the lower target, the firm maintained its Overweight rating on the stock.
The revision reflects a recalibration of expectations, with the firm citing several potential avenues for CVS Health to achieve margin expansion in the coming years. According to Piper Sandler, CVS Health has the opportunity to expand its Medicare Advantage (MA) margins by 100-200 basis points by calendar year 2025 (CY25).
The firm's analyst highlighted the company's strong Star ratings, which are seen as providing a clear path to sustained earnings growth into the next rate cycle. The prestigious Star ratings are anticipated to bolster the Aetna MA franchise, which is part of CVS Health's offerings.
The new price target of $64 is based on a consistent 10x multiple of the revised calendar year 2026 estimated adjusted earnings per share (EPS). Piper Sandler's outlook suggests that the firm remains confident in CVS Health's performance and prospects despite the adjustment.
The Overweight rating indicates that Piper Sandler continues to view CVS Health as a favorable investment compared to other stocks in the market, expecting it to outperform the average market return. The price target reduction comes with an optimistic view on the company's ability to grow earnings through strategic initiatives and a strong position in the market.
In other recent news, CVS Health has seen several significant developments. The company's third-quarter earnings report showed an adjusted earnings per share of $1.09, with total revenues exceeding $95 billion, marking a 6% increase year-over-year.
However, CVS Health faced challenges in its healthcare benefits segment, particularly within Aetna, due to pricing miscalculations and industry pressures. Leerink Partners and RBC (TSX:RY) Capital Markets both adjusted their outlook on CVS Health, reducing their price targets from $63.00 to $57.00 and $68 to $58 respectively, while maintaining their ratings on the stock.
The company announced leadership changes, with the appointment of new CEO Dave Joyner and Steve Nelson, a former executive of UnitedHealth Group (NYSE:UNH)'s Mayo Clinic, as head of Aetna. CVS Health also revealed plans to close approximately 270 stores by 2025 as part of an optimization strategy and is working on a multi-year cost savings initiative expected to generate over $500 million in 2025. These recent developments reflect CVS Health's broader strategy to address the challenges it faces and return the Health Care Benefits segment to normal profitability levels.
InvestingPro Insights
Adding to Piper Sandler's analysis, InvestingPro data provides further context on CVS Health's financial position. The company's P/E ratio of 11.8 (adjusted for the last twelve months) suggests that the stock may be undervalued relative to its earnings, aligning with Piper Sandler's Overweight rating. This valuation metric, coupled with a price-to-book ratio of 0.97, indicates that CVS is trading close to its book value, potentially offering value to investors.
InvestingPro Tips highlight that CVS has maintained dividend payments for 54 consecutive years and has raised its dividend for 3 consecutive years. This consistent dividend history, combined with a current dividend yield of 4.59%, may appeal to income-focused investors, especially given the firm's expectation of sustained earnings growth.
The company's revenue growth of 5.96% over the last twelve months and a quarterly growth of 6.02% in Q3 2024 demonstrate CVS's ability to expand its top line, which could support the margin expansion opportunities mentioned by Piper Sandler.
For investors seeking a deeper understanding of CVS Health's potential, InvestingPro offers additional tips and insights. The platform currently lists 8 more tips for CVS, providing a comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.